Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
about
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agentsComparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myelomaNY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Response evaluation and monitoring of multiple myeloma.What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Oligoclonal Bands of Immunoglobulins in Serum Leading to Diagnosis of Human Immunodeficiency Virus 1 Infection.Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agentPrognostic value of unrelated atypical serum immunofixation patterns during multiple myeloma therapy.For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission.
P2860
Q33695919-2255EAED-E563-4438-98A4-1F21FF77D4E8Q34413764-A4A45347-5589-41A0-A6EC-91765F383B74Q34451635-BBE8064A-211B-425B-BFAB-E494467FDDEAQ34454581-895813E9-3E07-4542-8D49-2FAF80212E0DQ34485950-A478B4D4-F34E-4A8F-90EA-1CAC0A58CF8DQ34649034-D005F746-7D65-4604-8D22-7759E92B6DB3Q35220381-443C664D-7B58-406A-9E76-CA4FFB4EED47Q36682832-BC6B7DB9-903D-419B-B6A8-F48438F7DAC5Q36967163-4E85AF3D-871D-4F24-B943-E4E64ABE10CFQ37795414-659898FF-CB1A-49C6-858F-083113961D5CQ38183872-D89FAEAD-16FB-4972-91E9-030AEA6F4FA6Q38256196-9E82652F-11CE-49F6-BD9A-56B7FA1FD15AQ38310281-69C04073-C617-4AB6-A02D-323916D76495Q38462720-59011877-E69B-4090-8852-DC1FF6FC8B05Q40809257-902AF30C-CB27-476A-8847-342F817BF4C1Q41327770-E821A1CF-CD8C-4606-BD6D-A9CC41311990Q41925897-7306D76A-85E0-44AF-A69F-B9A20CB655F2Q47390705-52E06F11-C951-4E98-92D6-3522C3652466
P2860
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Atypical serum immunofixation ...... f response in multiple myeloma
@ast
Atypical serum immunofixation ...... f response in multiple myeloma
@en
type
label
Atypical serum immunofixation ...... f response in multiple myeloma
@ast
Atypical serum immunofixation ...... f response in multiple myeloma
@en
prefLabel
Atypical serum immunofixation ...... f response in multiple myeloma
@ast
Atypical serum immunofixation ...... f response in multiple myeloma
@en
P2093
P2860
P1476
Atypical serum immunofixation ...... f response in multiple myeloma
@en
P2093
David Jayabalan
Ethel Cesarman
John P Leonard
Joong W Lee
Madhu Mazumdar
Morton Coleman
Paul J Christos
Richard Lent
Richard R Furman
Roger N Pearse
P2860
P304
P356
10.1111/J.1365-2141.2008.07374.X
P407
P577
2008-10-16T00:00:00Z